Baidu
map

指南&解读指南

订阅

MedSci主页 / 所有栏目 / 指南&解读指南

2019 AHA/ASA急性缺血性卒中早期管理指南全面解读（上）

2019-12-30 中国卒中杂志.2019,14(12):1263-1269.

急性缺血性卒中早期管理

2019更新版指南包括六大主题，涉及51个项目。这六个主题覆盖了从院前诊治到入院后48 h的管理。在244项推荐中，有75项标识为新推荐。

中文标题：

2019 AHA/ASA急性缺血性卒中早期管理指南全面解读（上）

发布机构：

发布日期：

2019-12-30

简要介绍：

2019更新版指南包括六大主题，涉及51个项目。这六个主题覆盖了从院前诊治到入院后48 h的管理。在244项推荐中，有75项标识为新推荐。

作者：编译：董漪 桂莉 郑华光 李玮 王秦润琪 程忻 高远 刘慧慧 丁红 窦鑫 谭泽锋 李淑娟 

拓展指南：与卒中相关指南：

相关资料下载：
[AttachmentFileName(sort=100, fileName=2019 AHA/ASA急性缺血性卒中早期管理指南全面解读（上）)] GetToolGuiderByIdResponse(projectId=1, id=ce20d1c00185e3e3, title=2019 AHA/ASA急性缺血性卒中早期管理指南全面解读（上）, enTitle=, guiderFrom=中国卒中杂志.2019,14(12):1263-1269., authorId=null, author=, summary=2019更新版指南包括六大主题，涉及51个项目。这六个主题覆盖了从院前诊治到入院后48 h的管理。在244项推荐中，有75项标识为新推荐。 , cover=, journalId=null, articlesId=null, associationId=null, associationName=, associationIntro=, copyright=0, guiderPublishedTime=Mon Dec 30 00:00:00 CST 2019, originalUrl=, linkOutUrl=, content=<P>2019更新版指南包括六大主题，涉及51个项目。这六个主题覆盖了从院前诊治到入院后48 h的管理。在244项推荐中，有75项标识为新推荐。 </P> <P>作者：编译：董漪 桂莉 郑华光 李玮 王秦润琪 程忻 高远 刘慧慧 丁红 窦鑫 谭泽锋 李淑娟 </P>拓展指南：<strong>与<font color=red>卒中</font>相关指南：</strong><br><ul><li><a href="//www.sandwebs.com/guideline/show_article.do?id=65e061c0018a9879" title="2019 卒中肺炎工作组共识：卒中并发肺炎的抗生素治疗" target=_blank>2019 卒中肺炎工作组共识：卒中并发肺炎的抗生素治疗</a></li> <li><a href="//www.sandwebs.com/guideline/show_article.do?id=e876f1c0018a9680" title="中国卒中吞咽障碍与营养管理手册" target=_blank>中国卒中吞咽障碍与营养管理手册</a></li> <li><a href="//www.sandwebs.com/guideline/show_article.do?id=5f5c91c0018a329f" title="中国卒中门诊建设规范" target=_blank>中国卒中门诊建设规范</a></li> <li><a href="//www.sandwebs.com/guideline/show_article.do?id=b5c581c00183ea0c" title="2019 AF-SCREEN 国际合作组织白皮书：卒中后房颤筛查" target=_blank>2019 AF-SCREEN 国际合作组织白皮书：卒中后房颤筛查</a></li> <li><a href="//www.sandwebs.com/guideline/show_article.do?id=a105a1c00183a059" title="卒中相关性肺炎诊治中国专家共识（2019更新版）" target=_blank>卒中相关性肺炎诊治中国专家共识（2019更新版）</a></li> 更多信息请点击：<a href="//www.sandwebs.com/guideline/list.do?q=%E5%8D%92%E4%B8%AD" target=_blank>有关卒中更多指南</a></ul>, tagList=[TagDto(tagId=4420, tagName=急性缺血性卒中), TagDto(tagId=69121, tagName=早期管理)], categoryList=[CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=解读, guiderLanguage=0, guiderRegion=0, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=6422, appHits=858, showAppHits=31, pcHits=2375, showPcHits=4864, likes=27, shares=72, comments=30, approvalStatus=1, publishedTime=Thu Jan 30 01:32:59 CST 2020, publishedTimeString=2019-12-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Thu Jan 30 01:32:59 CST 2020, updatedBy=null, updatedName=null, updatedTime=Fri Jan 05 10:32:21 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2019 AHA/ASA急性缺血性卒中早期管理指南全面解读（上）)])
2019 AHA/ASA急性缺血性卒中早期管理指南全面解读（上）
下载请点击：
评论区 (23)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1223478, encodeId=e30d12234e833, content=点赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c861636892, createdName=1dd9714fm03(暂无匿称), createdTime=Mon May 30 23:30:25 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012283, encodeId=ea561012283b4, content=收藏，很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220113/ebcbb3210da64051bf4c39e6c0a6835f/4b58baa9ab324260845281013f5f59df.jpg, createdBy=16725587400, createdName=ms2000000016859082, createdTime=Sat Aug 28 12:32:19 CST 2021, time=2021-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996850, encodeId=34d799685022, content=点赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f2d5542807, createdName=李鲁光, createdTime=Tue Jul 06 16:10:12 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970648, encodeId=01679e0648bb, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210601/a7f21ef4b0274511a87b59b8a5e9888e/13eaca1b6f0d436bb222eafb7ca7e980.jpg, createdBy=b69b5427070, createdName=人民万岁, createdTime=Thu Jun 03 18:18:23 CST 2021, time=2021-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963990, encodeId=44a4963990b7, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3afb5494740, createdName=ms9000000227597153, createdTime=Sun May 09 15:30:48 CST 2021, time=2021-05-09, status=1, ipAttribution=)]
    2022-05-30 1dd9714fm03(暂无匿称)

    点赞

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1223478, encodeId=e30d12234e833, content=点赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c861636892, createdName=1dd9714fm03(暂无匿称), createdTime=Mon May 30 23:30:25 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012283, encodeId=ea561012283b4, content=收藏，很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220113/ebcbb3210da64051bf4c39e6c0a6835f/4b58baa9ab324260845281013f5f59df.jpg, createdBy=16725587400, createdName=ms2000000016859082, createdTime=Sat Aug 28 12:32:19 CST 2021, time=2021-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996850, encodeId=34d799685022, content=点赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f2d5542807, createdName=李鲁光, createdTime=Tue Jul 06 16:10:12 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970648, encodeId=01679e0648bb, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210601/a7f21ef4b0274511a87b59b8a5e9888e/13eaca1b6f0d436bb222eafb7ca7e980.jpg, createdBy=b69b5427070, createdName=人民万岁, createdTime=Thu Jun 03 18:18:23 CST 2021, time=2021-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963990, encodeId=44a4963990b7, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3afb5494740, createdName=ms9000000227597153, createdTime=Sun May 09 15:30:48 CST 2021, time=2021-05-09, status=1, ipAttribution=)]
    2021-08-28 ms2000000016859082

    收藏，很实用

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1223478, encodeId=e30d12234e833, content=点赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c861636892, createdName=1dd9714fm03(暂无匿称), createdTime=Mon May 30 23:30:25 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012283, encodeId=ea561012283b4, content=收藏，很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220113/ebcbb3210da64051bf4c39e6c0a6835f/4b58baa9ab324260845281013f5f59df.jpg, createdBy=16725587400, createdName=ms2000000016859082, createdTime=Sat Aug 28 12:32:19 CST 2021, time=2021-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996850, encodeId=34d799685022, content=点赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f2d5542807, createdName=李鲁光, createdTime=Tue Jul 06 16:10:12 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970648, encodeId=01679e0648bb, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210601/a7f21ef4b0274511a87b59b8a5e9888e/13eaca1b6f0d436bb222eafb7ca7e980.jpg, createdBy=b69b5427070, createdName=人民万岁, createdTime=Thu Jun 03 18:18:23 CST 2021, time=2021-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963990, encodeId=44a4963990b7, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3afb5494740, createdName=ms9000000227597153, createdTime=Sun May 09 15:30:48 CST 2021, time=2021-05-09, status=1, ipAttribution=)]
    2021-07-06 李鲁光

    点赞

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1223478, encodeId=e30d12234e833, content=点赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c861636892, createdName=1dd9714fm03(暂无匿称), createdTime=Mon May 30 23:30:25 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012283, encodeId=ea561012283b4, content=收藏，很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220113/ebcbb3210da64051bf4c39e6c0a6835f/4b58baa9ab324260845281013f5f59df.jpg, createdBy=16725587400, createdName=ms2000000016859082, createdTime=Sat Aug 28 12:32:19 CST 2021, time=2021-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996850, encodeId=34d799685022, content=点赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f2d5542807, createdName=李鲁光, createdTime=Tue Jul 06 16:10:12 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970648, encodeId=01679e0648bb, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210601/a7f21ef4b0274511a87b59b8a5e9888e/13eaca1b6f0d436bb222eafb7ca7e980.jpg, createdBy=b69b5427070, createdName=人民万岁, createdTime=Thu Jun 03 18:18:23 CST 2021, time=2021-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963990, encodeId=44a4963990b7, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3afb5494740, createdName=ms9000000227597153, createdTime=Sun May 09 15:30:48 CST 2021, time=2021-05-09, status=1, ipAttribution=)]
    2021-06-03 人民万岁

    感谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1223478, encodeId=e30d12234e833, content=点赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c861636892, createdName=1dd9714fm03(暂无匿称), createdTime=Mon May 30 23:30:25 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012283, encodeId=ea561012283b4, content=收藏，很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220113/ebcbb3210da64051bf4c39e6c0a6835f/4b58baa9ab324260845281013f5f59df.jpg, createdBy=16725587400, createdName=ms2000000016859082, createdTime=Sat Aug 28 12:32:19 CST 2021, time=2021-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996850, encodeId=34d799685022, content=点赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f2d5542807, createdName=李鲁光, createdTime=Tue Jul 06 16:10:12 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970648, encodeId=01679e0648bb, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210601/a7f21ef4b0274511a87b59b8a5e9888e/13eaca1b6f0d436bb222eafb7ca7e980.jpg, createdBy=b69b5427070, createdName=人民万岁, createdTime=Thu Jun 03 18:18:23 CST 2021, time=2021-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963990, encodeId=44a4963990b7, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3afb5494740, createdName=ms9000000227597153, createdTime=Sun May 09 15:30:48 CST 2021, time=2021-05-09, status=1, ipAttribution=)]
    2021-05-09 ms9000000227597153

    很实用

    0

以上为热门评论，梅斯医学App还有更多内容

相关指南

2019 AHA/ASA指南：急性缺血性卒中的早期管理（更新版）

美国心脏协会(AHA,American Heart Association) · 2019-10-30

2019 韩国临床实践指南：急性缺血性卒中患者血管内再通治疗

韩国介入神经放射学学会(KSIN,Korean Society of Interventional Neuroradiology) · 2019-04-17

2019 ESO/ESMINT指南：急性缺血性卒中机械血栓清除术

欧洲卒中组织(ESO,European Stroke Organisation) · 2019-02-26

2019 SNIS报告：急性缺血性卒中紧急大血管闭塞血栓切除术的适应证

美国神经介入外科学会(SNIS,Society of NeuroInterventional Surgery) · 2019-01-04

2018 共识建议：脑出血，蛛网膜下腔出血以及急性缺血性卒中患者的目标温度管理

国外神经内科相关专家小组（统称） · 2018-09-25

2018 国际建议：急性缺血性卒中实践干预标准

亚澳介入和神经放射治疗联合会(AAFITN,Asian-Australian Federation of Interventional and Therapeutic Neuroradiology) · 2018-08-28

Baidu
map
Baidu
map
Baidu
map